IL2 and chronic graft versus host disease: The selective expansion of HELIOS+ Tregs and CD56br NK cells is consistent with previous findings in chronic graft-versus-host disease patients treated with daily dosing of LD-IL-2, using a mass cytometry approach40, demonstrating the high sensitivity of these immune subsets to LD-IL-2 treatment.